Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection
about
HIV-associated neurocognitive disorder--pathogenesis and prospects for treatmentChronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistencePaving the path to HIV neurotherapy: Predicting SIV CNS diseaseInterferon-alpha, immune activation and immune dysfunction in treated HIV infectionMonocytes as regulators of inflammation and HIV-related comorbidities during cARTDistinct phenotype, longitudinal changes of numbers and cell-associated virus in blood dendritic cells in SIV-infected CD8-lymphocyte depleted macaquesCD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cellsImmunologic Biomarkers, Morbidity, and Mortality in Treated HIV InfectionClinical Trials in Neurovirology: Successes, Challenges, and PitfallsChanges in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferonSwitch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.HIV-associated neurocognitive disorder.Host genetic factors predisposing to HIV-associated neurocognitive disorder.Residual immune dysregulation syndrome in treated HIV infection.Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individualsHeme oxygenase-1 dysregulation in the brain: implications for HIV-associated neurocognitive disorders.Can early therapy reduce inflammation?Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.CCR2 on CD14(+)CD16(+) monocytes is a biomarker of HIV-associated neurocognitive disorders.Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-aImmune activation in HIV-infected aging women on antiretrovirals--implications for age-associated comorbidities: a cross-sectional pilot study.Interactions between ageing and NeuroAIDS.JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals.Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disordersPlasma cytokine levels are related to brain volumes in HIV-infected individuals.Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial.SIV encephalitis lesions are composed of CD163(+) macrophages present in the central nervous system during early SIV infection and SIV-positive macrophages recruited terminally with AIDS.Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.Monocyte Traffic, Dorsal Root Ganglion Histopathology, and Loss of Intraepidermal Nerve Fiber Density in SIV Peripheral Neuropathy.Comparative Analysis of Cell-Associated HIV DNA Levels in Cerebrospinal Fluid and Peripheral Blood by Droplet Digital PCRCentral and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.Human immunodeficiency virus (HIV) modulates the associations between insulin resistance and cognition in the current combination antiretroviral therapy (cART) era: a study of the Women's Interagency HIV Study (WIHS).Associations between Cognition, Gender and Monocyte Activation among HIV Infected Individuals in NigeriaTracking the Emergence of Host-Specific Simian Immunodeficiency Virus env and nef Populations Reveals nef Early Adaptation and Convergent Evolution in Brain of Naturally Progressing Rhesus Macaques.Anaemia is associated with monocyte activation in HIV-infected adults on antiretroviral therapySoluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid.Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations
P2860
Q26766448-1A27BFC6-92F7-41BD-BE69-43F737B76297Q26825762-A35383F8-7804-415C-9A0A-74FE3D02FC92Q26852969-EBB4EDC7-E362-4E3B-A455-787120F0840DQ26861003-312A27E8-639C-4D14-A72C-EC9B707BED25Q27006827-5411AC88-7E57-42A4-B702-6B27C3856922Q27311668-2C8DDF21-8F46-4369-91FD-FA0ECCC05C31Q27322949-D56936A7-9DEA-45F6-8576-FFDA31A5CFFFQ30245379-DDE654AF-5B3D-4D21-8BED-00BA75E5469CQ30250271-F2B6AEAE-31B4-4E6C-AB58-02236AAAA7BBQ33877898-9C127A85-04AC-44E0-BF26-5B26850DCACCQ33934080-35157918-1FED-455B-9114-9AAA17C326EBQ33939729-15599E9F-5578-4EFB-8F45-7D8BEB8F7E88Q34001122-151EBABE-5A80-4CD3-A4A3-483AF6F72517Q34020121-0ED34539-8383-4A43-ABEE-D545497A1500Q34048920-39AF7289-48ED-4510-919F-E70AD23DE623Q34139883-87BF3D0D-A69D-454A-973D-2BDC5820618FQ34159822-ADC7401C-3D0B-48D3-BA53-38B6A21AF2B7Q34288534-E5830BA7-18F8-4DD2-BEA9-0965B07DF03DQ34315572-D8A59BEB-CED9-4F90-9C13-4625650ED51AQ34376412-A4FE1F5F-A560-4815-9421-65F6E124EB55Q34718135-7D367E48-3EA5-4C3C-8269-E48AD4FF66A6Q34749335-9C81EF91-DAED-48C0-902B-C53685F32878Q34977613-3E370347-BB61-48C7-8E73-56D5AC5A5688Q35005863-CA7DBC4B-AC0D-4E4B-A5E8-28C6AC41ABCCQ35125996-E24545A6-49EA-4A73-92ED-5A12DEC2E29BQ35154529-FBC13BF6-7A9F-4B09-B1EF-7A5418D4624CQ35572270-276E2F39-F4A1-4E01-952E-1BCBDBDA53BEQ35629714-316A93DC-2F22-4465-B995-9D22DF1ADD95Q35669020-283D339F-CBB5-4E78-99C3-279CC891332AQ35755634-5B77C5E1-E090-465D-8C78-2FA466A871B5Q35792802-EFBD08FA-C8DF-4899-8D01-5D5AA7DDCDFFQ35797131-AD92D2B3-4111-4149-BAF2-B08C6F3A458FQ35878624-D3F6B56B-2EF4-475C-9E91-7820B20B43E5Q35880399-F312D37D-062C-4C95-96DA-DC90223C1D9EQ35909822-AB9FE041-CBBA-4410-841E-079E0EE7A2A5Q35914315-2BE4EA79-2572-408C-B9B1-4706112DD059Q35935289-6EF216BB-EB8F-4AE8-81E0-C727CD9C90B1Q35996619-A25D02B7-9124-4D41-9ADC-D5B42A38C2A8Q36072424-892762C5-65AE-4CD9-AFA2-4AB0DFE01177Q36238501-781F9EEC-940C-4251-829D-56615554D653
P2860
Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Elevated sCD163 in plasma but ...... ve impairment in HIV infection
@en
Elevated sCD163 in plasma but ...... e impairment in HIV infection.
@nl
type
label
Elevated sCD163 in plasma but ...... ve impairment in HIV infection
@en
Elevated sCD163 in plasma but ...... e impairment in HIV infection.
@nl
prefLabel
Elevated sCD163 in plasma but ...... ve impairment in HIV infection
@en
Elevated sCD163 in plasma but ...... e impairment in HIV infection.
@nl
P2093
P2860
P50
P1433
P1476
Elevated sCD163 in plasma but ...... ve impairment in HIV infection
@en
P2093
Allison Weiffenbach
Kenneth C Williams
Tricia H Burdo
P2860
P304
P356
10.1097/QAD.0B013E32836010BD
P407
P577
2013-06-01T00:00:00Z